- Home
- WF vs MDGL Comparison
WF vs MDGL Comparison
Compare WF & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- MDGL
- Stock Information
- Founded
- WF 1899
- MDGL 2011
- Country
- WF South Korea
- MDGL United States
- Employees
- WF N/A
- MDGL N/A
- Industry
- WF Commercial Banks
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- WF Finance
- MDGL Health Care
- Exchange
- WF Nasdaq
- MDGL Nasdaq
- Market Cap
- WF 8.2B
- MDGL 6.8B
- IPO Year
- WF N/A
- MDGL N/A
- Fundamental
- Price
- WF $35.75
- MDGL $326.79
- Analyst Decision
- WF
- MDGL Buy
- Analyst Count
- WF 0
- MDGL 9
- Target Price
- WF N/A
- MDGL $386.29
- AVG Volume (30 Days)
- WF 80.7K
- MDGL 346.6K
- Earning Date
- WF 05-15-2025
- MDGL 05-01-2025
- Dividend Yield
- WF 5.16%
- MDGL N/A
- EPS Growth
- WF 22.27
- MDGL N/A
- EPS
- WF 2.67
- MDGL N/A
- Revenue
- WF $7,762,228,247.00
- MDGL $180,133,000.00
- Revenue This Year
- WF N/A
- MDGL $230.69
- Revenue Next Year
- WF $9.38
- MDGL $74.76
- P/E Ratio
- WF $4.49
- MDGL N/A
- Revenue Growth
- WF 20.71
- MDGL N/A
- 52 Week Low
- WF $29.44
- MDGL $189.00
- 52 Week High
- WF $38.05
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- WF 59.16
- MDGL 53.80
- Support Level
- WF $29.44
- MDGL $298.00
- Resistance Level
- WF $37.39
- MDGL $330.64
- Average True Range (ATR)
- WF 1.51
- MDGL 20.78
- MACD
- WF 0.36
- MDGL 1.35
- Stochastic Oscillator
- WF 79.41
- MDGL 88.57
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holdings company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. Its operating segments include Banking, Credit card, capital, Investment banking, and others.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.